Julu Medical Completes Tens of Millions RMB Series A Funding to Advance Cardiopulmonary Rehabilitation Center Development in China

VCBeatBeijing Julu Medical Management Co., Ltd., a provider of comprehensive cardiopulmonary rehabilitation solutions, learned at the earliest opportunity that (Jian(Julu Medical) recently completed tens of millionsYuanRenminbiSeries A financing, invested by Yijing Capital.Previously, Julu Medical had obtainedMiFang Capital、Tianyi Group、Dan En CapitalInvestment from renowned institutions such as。

Regarding this round of financing, Xu Changjun, Chairman of Julu Medical, stated, “The funds raised will be primarily used for the expansion and construction of rehabilitation centers, scaling up digital innovative medical devices, hardware R&D, and building our marketing and operations teams. Additionally, leveraging capital support and technological breakthroughs, Julu Medical will further promote the development of cardiopulmonary rehabilitation in China, benefiting more patients with cardiopulmonary diseases and helping them restore vitality and health.”

Julu Medical is a rehabilitation healthcare company dedicated to the systematic development and operation of cardiopulmonary rehabilitation diagnosis and treatment systems. It operates Beijing Julu Rehabilitation Medical Center Co., Ltd. (Rehabilitation Center) and Hangzhou Julu Medical Device Co., Ltd. (R&D Factory), and holds certifications as both a National High-Tech Enterprise and a Zhongguancun High-Tech Enterprise.

Since its establishment, Julu Medical has built a robust medical management team. Founder Xu Changjun possesses extensive experience in frontline team management; Chief Medical Officer Liu Sa specializes in Rehabilitation Medicine from Xiangya School of Medicine; and R&D Director Zhang Chenguang holds a Ph.D. from the Chinese Center for Disease Control and Prevention, having participated in multiple major national and provincial/ministerial-level scientific research projects.

Drawing on extensive experience, Julu Medical has collaborated with professional societies, academic leaders, and tertiary hospitals to establish a Cardiopulmonary Rehabilitation Academic Exchange Center. Serving also as a training base, the center provides comprehensive solutions—including talent development, system management, equipment supply, and operational strategies for cardiopulmonary rehabilitation—to promote the establishment of cardiopulmonary rehabilitation centers across China.

To date, Julu Medical has accumulated over 60 patents. The company is comprehensively advancing the implementation of cardiopulmonary rehabilitation through initiatives such as developing digital systems for cardiopulmonary rehabilitation management, providing managed operations and holistic solutions for cardiopulmonary rehabilitation centers, researching, developing, and manufacturing related medical equipment, and offering specialized training for cardiopulmonary physical therapists.

Xu Changjun revealed, “Julu Medical’s self-developed management system and rehabilitation products have covered clinical needs, possessing rigorous medical technology delivery capabilities and cardiopulmonary rehabilitation center operational capabilities,”Julu MedicalChina’s First Independently Operated Cardiopulmonary Rehabilitation Center WillYuThis May in BeijingGrand Opening and Operations。”

Public data indicate that China has a vast population with potential rehabilitation needs, with an estimated total of 170 million patients. Among them, traditional rehabilitation accounts for 9%, while rehabilitation for chronic diseases and the elderly constitutes as high as 91%. Furthermore, there are currently 330 million cardiovascular disease patients in China, the vast majority of whom do not receive appropriate rehabilitation therapy after treatment.

In addition, patients with chronic obstructive pulmonary disease (COPD), those who have undergone lung cancer surgery or percutaneous coronary intervention (PCI), and those with heart failure suffer from poor quality of life and endure significant physical and psychological distress, creating an urgent need for rehabilitation services. According to the “2019 Research Report on the Development Potential of the Rehabilitation Industry” released by VCBeat Institute,Projected by 2022，China's rehabilitation market size is projected to reach approximately RMB 103.3 billion.

From the perspective of rehabilitation market development, driven by national policies, field experts, industry associations, and other factors, China's rehabilitation sector is accelerating its growth.

In terms of policy, the state is placing increasing emphasis on the rehabilitation industry, explicitly encouraging its development in documents such as the Healthy China 2030 Planning Outline. Furthermore, as an indispensable component of the tiered diagnosis and treatment system, rehabilitation medicine is being rapidly promoted alongside the implementation of this system. The robust development of the rehabilitation industry helps to optimize the allocation of medical resources and improve their utilization efficiency.

In terms of talent development, the national-level University of Rehabilitation, jointly established by the China Disabled Persons’ Federation, the National Health Commission, and other departments under the supervision of Shandong Province, has completed its preparatory work. The main campus buildings are scheduled to be substantially completed in 2021. In the future, it will cultivate an increasing number of specialized rehabilitation professionals for China’s rehabilitation sector.

In terms of the industry, numerous renowned experts have jointly promoted the establishment of the Respiratory Rehabilitation Association and the Cardiac Rehabilitation Association, standardizing the sector while significantly advancing the development of cardiopulmonary rehabilitation.

It is foreseeable that, driven by numerous favorable factors such as supportive policies, talent availability, and industry associations, the cardiopulmonary rehabilitation market will experience rapid growth.

Yijing CapitalIndicates“We fully recognize Julu Medical’s business model, industry positioning, and technical capabilities in the field of cardiopulmonary rehabilitation. In the future, we will leverage our own advantages and resources to support the operation of Julu Cardiopulmonary Rehabilitation Centers, the development of its CSM digital management system, and the creation of comprehensive cardiopulmonary rehabilitation solutions, thereby providing users with standardized medical services that integrate ‘hardware + software + delivery’ as a triad, and continuously promoting the development of China’s cardiopulmonary rehabilitation sector.”

Xin Jifu, Managing Partner at Danen Capital, believes that: “Our investment in early-stage enterprises has always adhered to three criteria: first, entrepreneurs with an entrepreneurial spirit; second, dynamic organizations; and third, a generally correct strategic direction.

First, Mr. Xu is a seasoned serial entrepreneur whose previous venture was highly successful. Moreover, he possesses an open mindset and strong adaptive capabilities. We are very optimistic about Mr. Xu and his entrepreneurial team.

Secondly, the core team of Julu Medical is highly stable and operates as a dynamic learning organization. In facing new domains, this team continuously explores and iterates through trial and error, seizing significant market opportunities at minimal cost.

Finally, we remain firmly bullish on the field of cardiopulmonary rehabilitation. In the cardiovascular sector, numerous large companies have emerged across pharmaceuticals, high-value consumables, and in vitro diagnostics (IVD). For instance, enterprises such as Lepu Medical and MicroPort Medical have rapidly risen by addressing the clinical needs of the cardiovascular patient population. We are fully confident that at least one highly outstanding large enterprise will likewise emerge in the rehabilitation segment serving this same patient demographic. Although the rehabilitation market is still in its early stages, we see immense market potential based on feedback from both patients and physicians. We believe that the cardiopulmonary rehabilitation market will become a vital component of the cardiovascular sector and will eventually unleash its full potential.

Yijing Capital, established in 2015, engages in primary market equity investments and fund-of-funds investments using its own capital and private equity funds. Adhering to the philosophy of “helping enterprises innovate and grow, promoting industrial optimization and upgrading, and driving social development and progress,” Yijing Capital focuses on sectors such as healthcare, TMT & mass consumption, and hard-core technologies. It specializes in investing in start-up and growth-stage companies that deliver high value creation and technological innovation. In the healthcare sector, it has invested in multiple leading companies in niche industries, including Weier’nuo Pediatrics, Dayi Group, Hanyu Medical, Shuchuang Robotics, Zhidao Biology, and MedSci.

Danen Capital, established in 2012, is an evergreen fund initiated by entrepreneurs that spans both primary and secondary markets. We focus on sectors such as hard technology, healthcare, and consumer goods, seeking to invest in outstanding companies with long-term value. The Danen team comprises professionals with extensive experience in investment and capital markets, industry partners, and serial successful entrepreneurs. Having collaborated stably for over eight years, we have formed a synergistic team driven by three core engines. Our post-investment team has years of proven success in empowering high-growth enterprises, helping them address three major challenges: performance, management, and talent. By leveraging unique coaching and consulting tools, we assist founders and their organizations in achieving concurrent upgrades.

Med-Fine Capital is a specialized investment fund focused on the pharmaceutical, healthcare, and life sciences sectors. Its management team possesses deep industry expertise in pharmaceuticals and healthcare, along with extensive venture capital experience. Med-Fine Capital has completed investments in approximately forty emerging companies, including Tianguangshi (antibody drugs), Hanyu Medical (interventional devices), Zanrong Pharma (novel drug R&D), Qiuzhen Medicine (tumor sequencing), Lingke Pharmaceuticals (novel drug R&D), Ansong Technology (orthopedic devices), Jiajian Medicine (genetic sequencing), Weimicro Biology (POCT), and Saifu Pharma (CRO). Upholding the philosophy of “focusing on pharmaceuticals, healthcare, and life sciences, leveraging capital value, and rewarding trust,” Med-Fine Capital is committed to becoming an open, platform-oriented professional pharmaceutical investment fund with prominent international competitiveness and widespread renown.

Tianyi Group, the parent company of Meinian Onehealth, is dedicated to investments in the healthcare sector. Its portfolio includes Meinian Onehealth (an A-share listed company), Wandong Medical (an A-share listed company), Minsheng ENT Hospital, Meivie Dental, Meiao Dental, Daxiang Doctor, U-Health, and Meiyingenics. The group also operates the Health Intelligence Valley incubator and Zhongwei Fund, a specialized healthcare investment platform.